Mineralys Therapeutics:Lorundrostat在伴或不伴慢性肾病的参与者中展现为期12周的优良安全性特征

美股速递
May 30

Mineralys Therapeutics公司宣布,其研究性药物Lorundrostat在为期12周的临床试验中,于伴有或不伴有慢性肾病的参与者群体内均表现出良好的安全性特征。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10